Jin Medical International Ltd.(ZJYL)Earnings, Financials & Key Ratios

ZJYL•NASDAQ

16.5× P/E·Price updated Jun 19, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryRehabilitation and mobility aids

AboutJin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.Show more

Revenue$21M-12.0%
EBITDA$933K-76.6%
Net Income$1M-67.6%
EPS (Diluted)0.15-68.1%
Gross Margin29.22%-27.7%
EBITDA Margin4.51%-73.4%
Operating Margin2.94%-81.0%
Net Margin5.76%-63.2%
ROE4.1%-70.7%

ZJYL Key Insights

Jin Medical International Ltd. (ZJYL) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 12.5%
✓Trading at only 0.7x book value

✗Weaknesses

✗Profits declining 11.6% over 5 years
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when ZJYL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

ZJYL Price & Volume

Jin Medical International Ltd. (ZJYL) stock price & volume — 10-year historical chart

Loading chart...

ZJYL Growth Metrics

Jin Medical International Ltd. (ZJYL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years5.02%

3 Years2.53%

TTM13.27%

Profit CAGR

10 Years-

5 Years-11.59%

3 Years-23.93%

TTM-12.85%

EPS CAGR

10 Years-

5 Years6.4%

3 Years-27.89%

TTM-23.19%

Return on Capital

10 Years22.48%

5 Years13.26%

3 Years10.18%

Last Year2.09%

ZJYL Recent Earnings

Jin Medical International Ltd. (ZJYL) EPS & revenue vs analyst estimates — last 1 quarters

Full history →

Q1 2026Latest

Jan 23, 2026

Metric

Actual

Est

EPS

$0.16

—

Rev

$11M

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Jan 23, 2026	$0.16	$11M

Based on last 1 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
MPWRMonolithic Power Systems, Inc.Direct Competitor	76.81B	1563.70	122.64	26.43%	22.07%	17.89%	0.01
NVCRNovoCure LimitedDirect Competitor	1.62B	14.28	-11.70	8.28%	-25.66%	-50.82%	0.85
LFUSLittelfuse, Inc.Direct Competitor	12.13B	479.82	-165.46	8.92%	-1.61%	-1.57%	0.39
GKOSGlaukos CorporationDirect Competitor	7.65B	130.68	-39.84	32.33%	-34.34%	-26.46%	0.21
INVAInnoviva, Inc.Product Competitor	1.66B	22.49	6.82	18.52%	118.91%	47.59%	0.23
OSUROraSure Technologies, Inc.Product Competitor	305.85M	4.25	-4.52	-38.1%	-61.93%	-15.09%	0.04
LMATLeMaitre Vascular, Inc.Product Competitor	2.14B	93.95	37.28	13.53%	24.35%	16.19%	0.47
ATRCAtriCure, Inc.Product Competitor	1.46B	28.80	-120	14.88%	-0.83%	-0.95%	0.18

Compare ZJYL vs Peers

Jin Medical International Ltd. (ZJYL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MPWR

Most directly comparable listed peer for ZJYL.

Scale Benchmark

vs SYK

Larger-name benchmark to compare ZJYL against a more recognizable public peer.

Peer Set

Compare Top 5

vs MPWR, NVCR, LFUS, GKOS

ZJYL Income Statement

Jin Medical International Ltd. (ZJYL) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Metric	Sep'18	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25
Sales/Revenue	20.91M	20.37M	16.19M	20.76M	19.19M	19.82M	23.5M	20.69M
Revenue Growth %	-	-2.61%	-20.49%	28.22%	-7.58%	3.29%	18.57%	-11.98%
Cost of Goods Sold	13.25M	12.86M	10.7M	14.4M	12.99M	13.04M	14M	14.64M
COGS % of Revenue	63.38%	63.12%	66.05%	69.36%	67.7%	65.77%	59.57%	70.78%
Gross Profit	7.66M▲ 0%	7.51M▼ 1.9%	5.5M▼ 26.8%	6.36M▲ 15.7%	6.2M▼ 2.6%	6.78M▲ 9.5%	9.5M▲ 40.1%	6.04M▼ 36.4%
Gross Margin %	36.62%	36.88%	33.95%	30.64%	32.3%	34.23%	40.43%	29.22%
Gross Profit Growth %	-	-1.91%	-26.8%	15.69%	-2.56%	9.46%	40.06%	-36.39%
Operating Expenses	3.33M	3.11M	3.14M	3.73M	4.07M	3.92M	5.86M	5.44M
OpEx % of Revenue	15.94%	15.26%	19.41%	17.96%	21.2%	19.76%	24.95%	26.28%
Selling, General & Admin	2.23M	1.98M	1.88M	2.16M	2.18M	2.37M	4.37M	3.88M
SG&A % of Revenue	10.66%	9.71%	11.62%	10.42%	11.34%	11.98%	18.58%	18.75%
Research & Development	1.2M	1.13M	1.26M	1.57M	1.89M	1.54M	1.5M	1.56M
R&D % of Revenue	5.75%	5.55%	7.79%	7.55%	9.86%	7.78%	6.37%	7.53%
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income	4.23M▲ 0%	4.4M▲ 4.2%	2.35M▼ 46.5%	2.63M▲ 11.8%	2.13M▼ 19.0%	2.87M▲ 34.6%	3.64M▲ 26.9%	608.18K▼ 83.3%
Operating Margin %	20.22%	21.62%	14.54%	12.67%	11.1%	14.47%	15.48%	2.94%
Operating Income Growth %	-	4.17%	-46.53%	11.76%	-19.04%	34.58%	26.91%	-83.29%
EBITDA	4.6M	4.75M	2.68M	2.97M	2.49M	3.09M	3.98M	932.87K
EBITDA Margin %	21.98%	23.31%	16.55%	14.32%	12.96%	15.61%	16.96%	4.51%
EBITDA Growth %	-	3.31%	-43.56%	10.94%	-16.31%	24.33%	28.83%	-76.59%
D&A (Non-Cash Add-back)	368.26K	344.04K	324.93K	341.25K	357.27K	225.9K	346.13K	324.68K
EBIT	4.23M	4.4M	2.47M	2.89M	2.74M	2.87M	3.64M	608.18K
Net Interest Income	0	0	-112.4K	-9.49K	181.6K	182.68K	466.52K	789.07K
Interest Income	25.24K	0	0	0	181.6K	182.68K	466.52K	789.07K
Interest Expense	0	22.85K	112.4K	9.49K	0	0	0	0
Other Income/Expense	71.02K	-276.61K	-1.52K	248.84K	612.11K	354.68K	544.97K	987.63K
Pretax Income	4.3M▲ 0%	4.13M▼ 4.0%	2.35M▼ 43.0%	2.88M▲ 22.4%	2.74M▼ 4.8%	3.22M▲ 17.5%	4.18M▲ 29.9%	1.6M▼ 61.9%
Pretax Margin %	20.56%	20.26%	14.53%	13.87%	14.29%	16.25%	17.8%	7.71%
Income Tax	616.88K	479.63K	147.15K	248.64K	36.11K	343.71K	763.88K	214.57K
Effective Tax Rate %	14.35%	11.62%	6.25%	8.63%	1.32%	10.67%	18.26%	13.45%
Net Income	3.68M▲ 0%	3.65M▼ 0.9%	2.21M▼ 39.5%	2.63M▲ 19.3%	2.71M▲ 2.8%	2.88M▲ 6.3%	3.68M▲ 27.7%	1.19M▼ 67.6%
Net Margin %	17.61%	17.91%	13.62%	12.67%	14.1%	14.52%	15.64%	5.76%
Net Income Growth %	-	-0.93%	-39.52%	19.3%	2.84%	6.34%	27.71%	-67.59%
Net Income (Continuing)	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.42M	1.38M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	-262.72K	-66.25K
EPS (Diluted)	0.18▲ 0%	0.18▼ 1.1%	0.11▼ 39.6%	0.20▲ 78.2%	0.40▲ 104.1%	0.40▼ 1.0%	0.47▲ 18.7%	0.15▼ 68.1%
EPS Growth %	-	-1.09%	-39.56%	78.18%	104.08%	-1%	18.69%	-68.09%
EPS (Basic)	0.18	0.18	0.11	0.20	0.40	0.40	0.47	0.15
Diluted Shares Outstanding	20M	20M	20M	13.38M	6.75M	7.26M	7.82M	7.83M
Basic Shares Outstanding	20M	20.01M	20.01M	13.38M	6.75M	7.26M	7.82M	7.83M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

ZJYL Balance Sheet

Jin Medical International Ltd. (ZJYL) balance sheet — assets, liabilities & shareholders' equity

Metric	Sep'18	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25
Total Current Assets	15.61M	17.7M	18.16M	19.42M	18.9M	31.12M	42.82M	44.14M
Cash & Short-Term Investments	2.45M	3.34M	2.84M	5.73M	7.07M	16.7M	26.76M	29.63M
Cash Only	853.3K	1.94M	1.66M	3.67M	4.79M	6.93M	8.14M	7.46M
Short-Term Investments	1.6M	1.4M	1.18M	2.05M	2.28M	9.77M	18.62M	22.17M
Accounts Receivable	6.34M	8.63M	7.86M	5.98M	4.25M	8.5M	8.78M	6.8M
Days Sales Outstanding	110.7	154.59	177.19	105.11	80.87	156.53	136.29	120.02
Inventory	6.06M	5.74M	7.25M	7.04M	6.88M	5.86M	7.12M	4.92M
Days Inventory Outstanding	166.91	162.85	247.51	178.44	193.31	163.98	185.58	122.72
Other Current Assets	745.95K	333.06K	-83.47K	523.47K	544.9K	60K	0	153.75K
Total Non-Current Assets	3.07M	2.66M	2.66M	2.48M	2.04M	1.79M	2.98M	9.23M
Property, Plant & Equipment	2.74M	2.38M	2.31M	2.11M	1.63M	1.48M	1.72M	7.98M
Fixed Asset Turnover	7.62x	8.57x	7.02x	9.83x	11.79x	13.39x	13.69x	2.59x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	189.34K	177.29K	180.89K	185.1K	163.21K	154.36K	1.15M	1.1M
Long-Term Investments	0	-177	-366.43K	0	-245	-152.47K	0	0
Other Non-Current Assets	140.16K	15.53K	366.43K	0	245	152.47K	0	0
Total Assets	18.68M▲ 0%	20.36M▲ 9.0%	20.82M▲ 2.2%	21.9M▲ 5.2%	20.94M▼ 4.4%	32.9M▲ 57.1%	45.8M▲ 39.2%	53.37M▲ 16.5%
Asset Turnover	1.12x	1.00x	0.78x	0.95x	0.92x	0.60x	0.51x	0.39x
Asset Growth %	-	9.01%	2.23%	5.22%	-4.39%	57.14%	39.2%	16.52%
Total Current Liabilities	9.68M	9.66M	10.01M	7.87M	5.7M	8.92M	17.15M	23.8M
Accounts Payable	7.75M	4.76M	5.43M	5.35M	4.11M	3.39M	3.01M	3.26M
Days Payables Outstanding	213.31	135.18	185.45	135.61	115.57	94.94	78.54	81.18
Short-Term Debt	712.53K	2.87M	2.65M	0	0	4.11M	11.32M	18.84M
Deferred Revenue (Current)	0	1.02M	975.65K	1.68M	830.3K	829.22K	797.08K	611.23K
Other Current Liabilities	669.25K	1.56M	306.28K	0	366.16K	272.55K	0	388.04K
Current Ratio	1.61x	1.83x	1.81x	2.47x	3.31x	3.49x	2.50x	1.86x
Quick Ratio	0.99x	1.24x	1.09x	1.57x	2.11x	2.83x	2.08x	1.65x
Cash Conversion Cycle	64.3	182.26	239.25	147.95	158.62	225.57	243.33	161.56
Total Non-Current Liabilities	0	0	0	0	0	0	96.17K	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	96.17K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	9.68M	9.66M	10.01M	7.87M	5.7M	8.92M	17.25M	23.8M
Total Debt	712.53K	2.87M	2.65M	0	0	4.11M	11.6M	18.91M
Net Debt	-140.77K	929.86K	983.72K	-3.67M	-4.79M	-2.82M	3.47M	11.45M
Debt / Equity	0.08x	0.27x	0.25x	-	-	0.17x	0.41x	0.64x
Debt / EBITDA	0.16x	0.60x	0.99x	-	-	1.33x	2.91x	20.27x
Net Debt / EBITDA	-0.03x	0.20x	0.37x	-1.24x	-1.93x	-0.91x	0.87x	12.27x
Interest Coverage	-	192.76x	21.93x	304.45x	-	-	-	-
Total Equity	9M▲ 0%	10.71M▲ 18.9%	10.8M▲ 0.9%	14.03M▲ 29.9%	15.24M▲ 8.6%	23.98M▲ 57.4%	28.55M▲ 19.1%	29.57M▲ 3.6%
Equity Growth %	-	18.93%	0.91%	29.87%	8.6%	57.39%	19.07%	3.57%
Book Value per Share	0.45	0.54	0.54	1.05	2.26	3.30	3.65	3.78
Total Shareholders' Equity	9M	10.71M	10.8M	14.03M	15.24M	23.98M	28.82M	29.64M
Common Stock	20K	20K	6.75K	6.75K	6.75K	7.8K	7.83K	7.83K
Retained Earnings	4.87M	8.52M	9.6M	11.89M	14.41M	16.93M	20.02M	20.94M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	461.44K	43.2K	1.11M	2.06M	740.29K	606.52K	2.04M	1.94M
Minority Interest	0	0	0	0	0	0	-262.72K	-66.25K

ZJYL Cash Flow Statement

Jin Medical International Ltd. (ZJYL) cash flow — operating, investing & free cash flow history

Metric	Sep'18	Sep'19	Sep'20	Sep'21	Sep'22	Sep'23	Sep'24	Sep'25
Cash from Operations	-2.39M	-1.33M	2.5M	5.84M	1.58M	3.11M	-1.21M	2.9M
Operating CF Margin %	-11.45%	-6.51%	15.46%	28.14%	8.24%	15.67%	-5.14%	14.04%
Operating CF Growth %	-	44.64%	288.85%	133.43%	-72.95%	96.53%	-138.86%	340.5%
Net Income	3.68M	3.65M	2.21M	2.63M	2.71M	2.88M	3.42M	1.38M
Depreciation & Amortization	368.26K	344.04K	329.91K	346.61K	362.6K	225.9K	346.13K	350.68K
Stock-Based Compensation	0	0	0	0	0	0	0	0
Deferred Taxes	0	-30.36K	-77.92K	-1.66K	-86.02K	89.6K	36.33K	-22.07K
Other Non-Cash Items	569.69K	5.47M	80.05K	-91.31K	28.94K	113.48K	-89.93K	97.98K
Working Capital Changes	-7.01M	-5.32M	-34.86K	2.96M	-1.43M	-200.81K	-4.92M	1.1M
Change in Receivables	-3.97M	-2.21M	1.12M	3.08M	333.66K	-376.08K	-3.91M	2.27M
Change in Inventory	-1.77M	248.34K	-1.37M	458.61K	-504.39K	1.56M	80.31K	168.29K
Change in Payables	0	-2.79M	425.9K	-369.08K	-810.34K	-646.89K	-499.57K	287.04K
Cash from Investing	1.96M	126.94K	-1.96M	-1.07M	-120.9K	-7.73M	-9.51M	-10.79M
Capital Expenditures	-187.68K	-73.33K	-142.32K	-42.88K	-40.17K	-113.94K	-144.95K	-6.63M
CapEx % of Revenue	0.9%	0.36%	0.88%	0.21%	0.21%	0.57%	0.62%	32.05%
Acquisitions	0	0	207	0	0	0	0	-500K
Investments	-	-	-	-	-	-	-	-
Other Investing	2.15M	54.85K	-2.1M	-215.03K	364.43K	10.14K	-978.93K	444
Cash from Financing	-3.19M	2.36M	-343.91K	-2.87M	121.86K	6.91M	11.65M	7.35M
Debt Issued (Net)	0	0	-355.32K	-2.77M	0	4.25M	6.87M	7.59M
Equity Issued (Net)	0	0	0	0	0	8M	312K	0
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	-3.19M	2.36M	11.42K	-103.88K	121.86K	-5.34M	4.48M	-237.88K
Net Change in Cash	-3.59M▲ 0%	1.09M▲ 130.4%	-278.44K▼ 125.6%	2.01M▲ 821.4%	1.12M▼ 44.2%	2.14M▲ 90.7%	1.21M▼ 43.5%	-674.55K▼ 155.9%
Free Cash Flow	-2.58M▲ 0%	-1.4M▲ 45.8%	2.36M▲ 268.8%	5.8M▲ 145.7%	1.54M▼ 73.4%	2.99M▲ 94.3%	-2.33M▼ 177.9%	-3.73M▼ 59.8%
FCF Margin %	-12.35%	-6.87%	14.58%	27.93%	8.03%	15.1%	-9.92%	-18.01%
FCF Growth %	-	45.82%	268.78%	145.69%	-73.44%	94.25%	-177.91%	-59.82%
FCF per Share	-0.13	-0.07	0.12	0.43	0.23	0.41	-0.30	-0.48
FCF Conversion (FCF/Net Income)	-0.65x	-0.36x	1.13x	2.22x	0.58x	1.08x	-0.33x	2.44x
Interest Paid	0	0	136.55K	68.78K	0	5.32K	239.37K	411.07K
Taxes Paid	0	0	522.11K	302.25K	47.44K	142.73K	205.37K	564.79K

ZJYL Key Ratios

Jin Medical International Ltd. (ZJYL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	40.9%	37.02%	20.51%	21.2%	18.5%	14.68%	14%	4.1%
Return on Invested Capital (ROIC)	35.78%	32.23%	15.08%	17.83%	15.36%	13.61%	10.26%	1.25%
Gross Margin	36.62%	36.88%	33.95%	30.64%	32.3%	34.23%	40.43%	29.22%
Net Margin	17.61%	17.91%	13.62%	12.67%	14.1%	14.52%	15.64%	5.76%
Debt / Equity	0.08x	0.27x	0.25x	-	-	0.17x	0.41x	0.64x
Interest Coverage	-	192.76x	21.93x	304.45x	-	-	-	-
FCF Conversion	-0.65x	-0.36x	1.13x	2.22x	0.58x	1.08x	-0.33x	2.44x
Revenue Growth	-	-2.61%	-20.49%	28.22%	-7.58%	3.29%	18.57%	-11.98%

ZJYL Frequently Asked Questions

Jin Medical International Ltd. (ZJYL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Jin Medical International Ltd. (ZJYL) reported $44.2M in revenue for fiscal year 2025. This represents a 111% increase from $20.9M in 2018.

Jin Medical International Ltd. (ZJYL) saw revenue decline by 12.0% over the past year.

Yes, Jin Medical International Ltd. (ZJYL) is profitable, generating $4.9M in net income for fiscal year 2025 (5.8% net margin).

Dividend & Returns

Jin Medical International Ltd. (ZJYL) has a return on equity (ROE) of 4.1%. This is below average, suggesting room for improvement.

Jin Medical International Ltd. (ZJYL) had negative free cash flow of $5.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ZJYL back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

How much would $100/month in ZJYL be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →

Jin Medical International Ltd.(ZJYL)Earnings, Financials & Key Ratios

ZJYL•NASDAQ

16.5× P/E·Price updated Jun 19, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryRehabilitation and mobility aids

Revenue$21M-12.0%
EBITDA$933K-76.6%
Net Income$1M-67.6%
EPS (Diluted)0.15-68.1%
Gross Margin29.22%-27.7%
EBITDA Margin4.51%-73.4%
Operating Margin2.94%-81.0%
Net Margin5.76%-63.2%
ROE4.1%-70.7%